Proving her illness created an illusion of wellness for columnist Ahna Crum, but a relapse after nine years showed her she ...

Disability progression in relapsing MS tends to follow one of four distinct patterns, according to a new study.

The quest to understand and slow disease progression in multiple sclerosis (MS) continued in 2024, with research revealing possible new treatments and furthering knowledge about the disease course.

“Now, it means that we are not treating patients with therapies that should reduce and, in many cases, eliminate relapses,” she said, stressing that symptom change may not mean a relapse. “If a ...

Prenatal and early life sun exposure was associated with lower risk for relapse in children with pediatric-onset multiple sclerosis (MS), a new prospective cohort study showed. At least 30 minutes of ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in ...

Please provide your email address to receive an email when new articles are posted on . Data were analyzed from 709 participants given ozanimod or interferon in two different trials trials. At 6 ...

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosisParis, December 24, 2025.

Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...

Emerging science is shaking up what has been previously known about multiple sclerosis (MS), changing our understanding of the basic biology of the disease. For years, the classical picture of MS has ...

Sanofi SNY announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA), seeking ...